BlackRock, Inc. 13D and 13G filings for Ultragenyx Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-24 09:12 am Sale | 2025-03-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | BlackRock Inc. BLK | 4,820,931 5.100% | -417,469 (-7.97%) | Filing |
| 2024-01-29 3:26 pm Purchase | 2023-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | BlackRock Inc. BLK | 5,238,400 6.400% | 901,908 (+20.80%) | Filing |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | BlackRock Inc. BLK | 4,336,492 6.200% | 925,078 (+27.12%) | Filing |
| 2022-03-09 5:18 pm Sale | 2022-02-28 | 13G | Ultragenyx Pharmaceutical Inc. RARE | BlackRock Inc. BLK | 3,411,414 4.900% | -73,238 (-2.10%) | Filing |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | BlackRock Inc. BLK | 3,484,652 5.100% | -1,802,824 (-34.10%) | Filing |